Design Therapeutics Inc
DSGN3.960USD
+0.140+3.66%
收盤 08/04, 16:00（美東）報價延遲15分鐘
224.80M總市值
虧損本益比TTM
關於 Design Therapeutics Inc 公司
Design Therapeutics, Inc. 是一家生物技術公司。該公司從事 GeneTACT 分子的研究和開發，GeneTACT 分子是小分子基因靶向嵌合治療候選藥物，旨在通過解決遺傳性核苷酸重複擴增突變導致的疾病的根本原因來改善疾病。其弗裏德賴希共濟失調 (FA) 項目專注於開發改善疾病的治療方法。其 DT-216 旨在克服導致 FA 的 FXN 轉錄障礙。DT-216 處於 I 期臨牀試驗階段。該公司還致力於開發 DT-216，以實現更高的暴露量和長期給藥以治療 FA，稱爲 DT-216P2，它使用相同的藥物物質 DT-216。其 FECD 項目專注於開發一種可能改善疾病的 FECD 醫療治療方法 DT-168，目前處於 I 期臨牀試驗階段。其 HD 項目專注於開發一種可能改善疾病的 HD 治療方法。
公司簡介
公司代碼DSGN
公司名稱Design Therapeutics Inc
上市日期Mar 26, 2021
CEODr. Pratik Shah, Ph.D.
員工數量54
證券類型Ordinary Share
年結日Mar 26
公司地址6005 Hidden Valley Road
城市CARLSBAD
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92011
電話18582934900
網址https://www.designtx.com/
公司代碼DSGN
上市日期Mar 26, 2021
CEODr. Pratik Shah, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Christopher M. (Chris) Storgard, M.D.
Dr. Christopher M. (Chris) Storgard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Arsani H. William, M.D.
Dr. Arsani H. William, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Ansari (Aseem Z. Ph.D.)
13.51%
SR One Capital Management, LP
11.50%
Logos Global Management LP
7.43%
Quan Venture Fund II LP
7.04%
Light Irrevocable Trust.
6.75%
Other
53.77%
持股股東
持股股東
佔比
Ansari (Aseem Z. Ph.D.)
13.51%
SR One Capital Management, LP
11.50%
Logos Global Management LP
7.43%
Quan Venture Fund II LP
7.04%
Light Irrevocable Trust.
6.75%
Other
53.77%
股東類型
持股股東
佔比
Corporation
20.55%
Venture Capital
18.93%
Hedge Fund
15.58%
Individual Investor
15.54%
Investment Advisor
13.62%
Investment Advisor/Hedge Fund
8.75%
Private Equity
3.44%
Research Firm
0.58%
Pension Fund
0.09%
Other
2.92%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
236
55.16M
97.16%
-18.43M
2025Q1
248
55.19M
97.22%
-19.02M
2024Q4
263
54.33M
95.95%
-18.64M
2024Q3
271
52.86M
93.39%
-18.89M
2024Q2
270
52.91M
93.60%
-20.44M
2024Q1
269
51.55M
91.19%
-22.56M
2023Q4
256
52.68M
94.11%
-19.20M
2023Q3
248
54.08M
96.62%
-10.45M
2023Q2
240
59.86M
106.99%
-4.32M
2023Q1
237
59.61M
106.56%
-4.74M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Ansari (Aseem Z. Ph.D.)
7.67M
13.51%
--
--
Mar 31, 2025
SR One Capital Management, LP
6.53M
11.5%
--
--
Mar 31, 2025
Logos Global Management LP
4.22M
7.43%
--
--
Mar 31, 2025
Quan Venture Fund II LP
4.00M
7.04%
-133.00K
-3.22%
Mar 31, 2025
Light Irrevocable Trust.
3.83M
6.75%
--
--
Mar 31, 2025
Star Irrevocable Trust.
3.83M
6.75%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.20M
3.88%
-73.03K
-3.21%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.95M
3.44%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
1.82M
3.2%
-38.89K
-2.09%
Mar 31, 2025
Baker Bros. Advisors LP
1.74M
3.07%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Micro-Cap ETF
0.02%
Fidelity Enhanced Small Cap ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Schwab U.S. Small-Cap ETF
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
iShares Micro-Cap ETF
佔比0.02%
Fidelity Enhanced Small Cap ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0.01%
Schwab U.S. Small-Cap ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
